Target intelligence / Profile preview

Interleukin-10 receptor subunit beta (IL10RB)

Target
IL10RB
Molecular classification
Receptor, Cytokine receptor
01

Overview

Interleukin-10 receptor subunit beta (IL10RB) is a single-pass type I transmembrane protein that serves as a shared accessory subunit for several class II cytokine receptor complexes. It is essential for mediating signal transduction for interleukin-10 (IL-10), interleukin-22 (IL-22), interleukin-26 (IL-26), and type III interferons. Upon ligand binding, IL10RB associates with other receptor subunits (such as IL10RA or IFNLR1) to form a functional heterotetrameric complex, which activates downstream Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) signaling pathways, leading to STAT3 phosphorylation and the transcription of anti-inflammatory or antiviral genes. IL10RB plays a critical role in maintaining immune homeostasis, particularly in mucosal tissues like the gastrointestinal tract. Loss-of-function mutations in the IL10RB gene are strongly associated with very early-onset inflammatory bowel disease (VEO-IBD) and severe enterocolitis in infants. In therapeutic development, IL10RB is targeted by recombinant cytokines and fusion proteins, such as pegilodecakin and AMT-101, which act as agonists to harness the anti-inflammatory properties of IL-10 for treating autoimmune diseases or to stimulate CD8+ T-cell-mediated antitumor immunity in oncology.

Other names
IL-10 receptor subunit betaIL-10R subunit betaIL-10R2Interleukin-10 receptor subunit 2Cytokine receptor class-II member 4Cytokine receptor family 2 member 4CRF2-4CRFB4CDw210b
02

Mechanism of action

Agonism of the receptor complex to activate downstream JAK/STAT signaling, promoting anti-inflammatory pathways or stimulating CD8+ T-cell-mediated antitumor immunity.

03

Biological functions

Signal transductionImmune responseAntiviral defenseInflammatory response
04

Disease associations

InflammationInfectionCancerAutoimmune disease
05

Safety considerations

Severe early-onset inflammatory bowel disease (VEO-IBD) or enterocolitis associated with loss-of-function mutationsPotential pro-inflammatory effects under certain conditions due to pleiotropic cytokine signalingRisk of systemic immunosuppression or increased susceptibility to infectionsAutoimmune reactions or tissue-damaging inflammation mediated by B cells and CD8+ T cells
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

IL10RB expression levelIL10RB gene mutationIL10RB methylation status

Beyond the preview

Go deeper on Interleukin-10 receptor subunit beta (IL10RB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-10 receptor subunit beta (IL10RB).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call